Indivior PLC is a specialty pharmaceutical company that develops and markets treatments for addiction and substance use disorders. Established in 2014 as a standalone entity following a spin-off from Reckitt Benckiser Group, the company trades in the U.S. on the OTC market under the ticker INVVY. Headquartered in Slough, U.K., with key operations in North America, Indivior applies formulation science and regulatory expertise to address critical public health needs.
Indivior’s core product portfolio targets opioid use disorder (OUD) and alcohol use disorder (AUD). Its flagship therapies include Suboxone sublingual film, a buprenorphine-naloxone combination for OUD maintenance, and Sublocade, an extended-release buprenorphine injection offering a once-monthly dosing option. The company also markets Perseris, a long-acting risperidone injection for schizophrenia, while advancing a pipeline of novel formulations designed to improve patient adherence and treatment outcomes.
With manufacturing and commercial footprints across the United States, Europe, Canada, Australia, and select emerging markets, Indivior employs direct sales forces alongside strategic partnerships to broaden market access. Its supply chain encompasses specialized pharmaceutical facilities in North America and Europe, ensuring consistent production of complex dosage forms. Licensing agreements and collaborations extend the company’s reach into Asia and Latin America.
Leadership at Indivior is anchored by President and Chief Executive Officer Caren Thorogood, who brings extensive global pharmaceutical and consumer health experience. Under her guidance, the executive team emphasizes sustainable growth, robust research and development, and collaborative engagement with healthcare providers, payers, and patient communities to meet evolving needs in addiction medicine.
AI Generated. May Contain Errors.
